Threshold lifts at market issuance sales agreement to $17.58 million

MLV assists in raising funds for working capital, corporate purposes

By Devika Patel

Knoxville, Tenn., Jan. 20 - Threshold Pharmaceuticals, Inc. amended an at market issuance sales agreement on Jan. 20, increasing the amount to be sold to $17.58 million from $15 million.

The common stock offering was negotiated with agent MLV & Co., LLC, previously doing business as McNicoll, Lewis & Vlak LLC, on Oct. 29, according to an 8-K filed Friday with the Securities and Exchange Commission.

Proceeds will be used for working capital and other general corporate purposes.

Threshold is a biotechnology company based in Redwood City, Calif., that develops small molecule therapeutics for the potential treatment of cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.